<unk>  is indicated for the treatment of Alzheimer's disease. In July 2021, the U.S. Food and Drug Administration (FDA) limited the indication to people with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
Aducanumab
Evolocumab
Alirocumab
Emapalumab
Tralokinumab
Olaratumab
Ustekinumab
Anifrolumab